Characterization of a Highly effective protein substrate for analysis of JAK2V617F Activity

Experimental Hematology

Volumn 35, Issue 11, 2007, Pages 1624-1632

  Li, Zhe ^a,b   Xing, Shu ^a,b   Wang, Shaofeng ^a,b   Ho, Wanting Tina ^a   Zhao, Zhizhuang Joe ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXTRACT; ENZYME INHIBITOR; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; JANUS KINASE 2; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ESCHERICHIA COLI; HUMAN; MONONUCLEAR CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SCREENING; SENSITIVITY AND SPECIFICITY; WILD TYPE;

CLINICAL ENZYME TESTS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; HUMANS; JANUS KINASE 2; JANUS KINASES; MUTATION, MISSENSE; PHOSPHORYLATION; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY;

ESCHERICHIA COLI;

EID: 35448951230     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.07.003     Document Type: Article

References (39)

1. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
2. Verma A., Kambhampati S., Parmar S., and Platanias L.C. Jak family of kinases in cancer. Cancer Metastasis Rev 22 (2003) 423-434
3. Neubauer H., Cumano A., Muller M., Wu H., Huffstadt U., and Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93 (1998) 397-409
4. Parganas E., Wang D., Stravopodis D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 (1998) 385-395
5. Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 (1997) 1309-1312
6. Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 (1997) 2535-2540
7. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
8. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
9. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
10. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
11. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 (2005) 22788-22792
12. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 106 (2005) 1207-1209
13. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
14. Scott L.M., Campbell P.J., Baxter E.J., et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106 (2005) 2920-2921
15. Jelinek J., Oki Y., Gharibyan V., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
16. V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
17. Xu X., Zhang Q., Luo J., et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 109 (2007) 339-342
18. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
19. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
20. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1 (2006) e18
21. Bumm T.G., Elsea C., Corbin A.S., et al. Characterization of murine JAK2 V617F-positive myeloproliferative disease. Cancer Res 66 (2006) 11156-11165
22. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
23. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270
24. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468
25. Saharinen P., Vihinen M., and Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14 (2003) 1448-1459
26. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., and Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17 (1997) 2497-2501
27. Li Z., Xu M., Xing S., et al. Erlotinib effectively inhibits JAK2 V617F activity and polycythemia vera cell growth. J Biol Chem 282 (2007) 3428-3432
28. Zhao Z., Bouchard P., Diltz C.D., Shen S.H., and Fischer E.H. Purification and characterization of a protein tyrosine phosphatase containing SH2 domains. J Biol Chem 268 (1993) 2816-2820
29. Zhao Z., Shen S.H., and Fischer E.H. Stimulation by phospholipids of a protein-tyrosine phosphatase containing two src homology 2 domains. Proc Natl Acad Sci U S A 90 (1993) 4251-4255
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
31. Fischer E.H., Charbonneau H., and Tonks N.K. Protein tyrosine phosphatases. A diverse family of intracellular and transmembrane enzymes. Science 253 (1991) 401-406
32. Zhao Z.J., Vainchenker W., Krantz S.B., Casadevall N., and Constantinescu S.N. Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol 42 (2005) 221-229
33. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 (2006) 2452-2466
34. Tefferi A. JAK2 Mutations in polycythemia vera-molecular mechanisms and clinical applications. N Engl J Med 356 (2007) 444-445
35. Hoffman R., Prchal J.T., Samuelson S., Ciurea S.O., and Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 13 (2007) 64-72
36. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
37. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
38. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
39. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139